ASAlessandro Marins dos Santos

Alessandro Marins dos Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandro Marins dos Santos has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Andrea Alice Silva

    Universidade Federal Fluminense, Brazil; Universidade Federal Fluminense, Brazil

    1 shared publication
  • Bianca Perdigão Olivieri

    Affiliation Laboratory for Innovations on Therapy, Education and Bioproducts, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil

    1 shared publication
  • Caroline Ishihama Suzuki

    Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil

    1 shared publication
  • Caroline Mitiká Watanabe

    Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil

    1 shared publication
  • David N. Wald

    Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, USA

    1 shared publication
  • Fabio P.S. Santos

    Experimental Research Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil; Oncology and Hematology Center "Familia Dayan-Daycoval", Hospital Israelita Albert Einstein, São Paulo, Brazil

    1 shared publication

Latest Publications

  • Open Access

    An Extended Flow Cytometry Evaluation of ex Vivo Expanded NK Cells Using K562.Clone1, a Feeder Cell Line Manufactured in Brazil

    by Caroline Mitiká Watanabe, Caroline Ishihama Suzuki, Alessandro Marins dos Santos, Thiago Pinheiro Arrais Aloia, Grace Lee, David Wald, Oswaldo Keith Okamoto, Julia T. Cottas de Azevedo, Juliana Aparecida Preto de Godoy, Fabio P.S. Santos, et al.


  • Open Access

    CD8low T cells expanded following acute Trypanosoma cruzi infection and benznidazole treatment are a relevant subset of IFN-γ producers

    by Alessandro Marins-Dos-Santos, Bianca Perdigão Olivieri, Rafaella Ferreira-Reis, Juliana de Meis, Andrea Alice Silva, Tania C. de Araújo-Jorge, Joseli Lannes-Vieira, Vinicius Cotta-De-Almeida

    CD8 T cells are regarded as pivotal players in both immunoprotection and immunopathology following Trypanosoma cruzi infection. Previously, we demonstrated the expansion of CD8+ T lymphocytes in the spleen of T. cruzi-infected mice under treatment with benznidazole (N-benzyl-2-nitroimidazole acetamide; Bz), a drug available for clinical therapy. This finding underlies the concept that the beneficial effects of Bz on controlling acute T. cruzi infection are related to a synergistic process between intrinsic trypanocidal effect and indirect triggering of the active immune response. In the present study, we particularly investigated the effect of Bz treatment on the CD8+ T cell subset following T. cruzi infection. Herein we demonstrated that, during acute T. cruzi infection, Bz treatment reduces and abbreviates the parasitemia, but maintains elevated expansion of CD8+ T cells. Within this subset, a remarkable group of CD8low cells was found in both Bz-treated and non-treated infected mice. In Bz-treated mice, early pathogen control paralleled the lower frequency of recently activated CD8low cells, as ascertained by CD69 expression. However, the CD8low subset sustains significant levels of CD44highCD62Llow and CD62LlowT-bethigh effector memory T cells, in both Bz-treated and non-treated infected mice. These CD8low cells also comprise the main group of spontaneous interferon (IFN)-γ-producing CD8+ T cells. Interestingly, following in vitro anti-CD3/CD28 stimulation, CD8+ T cells from Bz-treated T. cruzi-infected mice exhibited higher frequency of IFN-γ+ cells, which bear mostly a CD8low phenotype. Altogether, our results point to the marked presence of CD8low T cells that arise during acute T. cruzi infection, with Bz treatment promoting their significant expansion along with a potential effector program for high IFN-γ production.